1. Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled RxEACH Trial 
Yazid N. Al Hamarneh, Ross T. Tsuyuki, Charlotte A. Jones, Braden Manns, Marcello Tonelli, Nairne Scott-Douglass, Kailash Jindal, Wendy Tink, Brenda R. Hemmelgarn 
American Journal of Kidney Diseases 
Volume 71, Issue 1, Pages (January 2018)
DOI: /j.ajkd
Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Study flow. Randomization refers to the original randomization in RxEACH (The Alberta Vascular Risk Reduction Community Pharmacy Project). More information about the number of the overall patients screened has been reported elsewhere.18 Abbreviation: CKD, chronic kidney disease.
American Journal of Kidney Diseases  , 42-51DOI: ( /j.ajkd )
Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Primary outcome, the difference in change in estimated cardiovascular (CV) risk between the intervention and control groups at 3 months, found a relative risk reduction of 20% (absolute reduction, 5.03; 95% confidence interval, ; P<0.001) in estimated CV risk over a 3-month period between the intervention and control groups, after adjusting for baseline values and the center effect. Vertical bars denote error bars.
American Journal of Kidney Diseases  , 42-51DOI: ( /j.ajkd )
Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions